Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Ulrike, Lorch"'
Autor:
Andrea Kuemmerle, Denis Gossen, Annick Janin, Andrew Stokes, Nada Abla, Maja Szramowska, Ulrike Lorch, Myriam El Gaaloul, Isabelle Borghini‐Fuhrer, Stephan Chalon
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 4, Pp n/a-n/a (2024)
Abstract Drug resistance to sulfadoxine‐pyrimethamine and amodiaquine threatens the efficacy of malaria chemoprevention interventions in children and pregnant women. Combining pyronaridine (PYR) and piperaquine (PQP), both components of approved an
Externí odkaz:
https://doaj.org/article/d70d40b00e2d4329bab91bab1adbd6b8
Autor:
Charles Mundy, James Bush, Joseph Cheriyan, Ulrike Lorch, Steffan Stringer, Jörg Taubel, Kirsty Wydenbach, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The Association for Human Pharmacology in the Pharmaceutical Industry’s annual meeting focused on current and impending challenges facing the United Kingdom’s (UK) pharmaceutical industry and how these opportunities can inspire innovation and bes
Externí odkaz:
https://doaj.org/article/51626447c4c045fea413a4054ce30cd8
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionTumor immunotherapy is designed to control malignancies through the host immune response but requires circumventing tumor-dysregulated immunomodulation through immunostimulation, relieving immunorepression, or a combination of both approa
Externí odkaz:
https://doaj.org/article/f0589e9d56a34145a00cdc6aa3094f75
Autor:
Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland, Oliver Pohl
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Nolasiban is an orally active oxytocin receptor antagonist being developed to increase the efficiency of assisted reproductive technologies. This study evaluated the pharmacokinetics, pharmacodynamics, and cardiac safety of nolasiban in 45 h
Externí odkaz:
https://doaj.org/article/941c758ff82c46db9ab0bd9fda565dc9
Autor:
Ryuichi Kambayashi, Hiroko Izumi-Nakaseko, Ai Goto, Yoshinori Takei, Akio Matsumoto, Ulrike Lorch, Jörg Täubel, Atsushi Sugiyama
Publikováno v:
The Journal of Toxicological Sciences. 48:169-178
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d46147c3cd31b6c107a0cd02ca049dcc
https://doi.org/10.2131/jts.48.169
https://doi.org/10.2131/jts.48.169
Autor:
Shahzadgai Khan, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Annelize Koch, Michael Hammond, Stuart Mair, Ulrike Lorch, Steffan Stringer, Jorg Taubel, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on impending change, innovation, and future challenges facing early phase drug development as we move into the second decade of the 21th century. The
Externí odkaz:
https://doaj.org/article/126a543321ad49788d3af82a37356081
Autor:
Simon Coates, Duolao Wang, Tomasz Pierscionek, Sara Fernandes, Dilshat Djumanov, Ulrike Lorch, Jörg Täubel
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Most UK hospitals, laboratories, and research institutions use uniform reference intervals (RI) that do not take into account known diurnal and racial variation in total white blood cells (WBC) count and its constituent parameters. These risks of exc
Externí odkaz:
https://doaj.org/article/51cc5242870b46cda644af7673f77490
Autor:
Susan Reijntjes, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Annelize Koch, Michael Hammond, Stuart Mair, Peter Scholes, Ulrike Lorch, Steffan Stringer, Jorg Taubel, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on the changing face of early phase drug development and opened with a keynote speech concerning the revolution in pharmaceutical medicine over the l
Externí odkaz:
https://doaj.org/article/142ed6f8be4d431691147e0fb3990447
Autor:
Line Marchand, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl, Dorothée Camilleri, Anne Freier, Dilshat Djumanov, Christopher S. Spencer, Ulrike Lorch, Jorg Taubel
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
Nolasiban is an orally active oxytocin receptor antagonist being developed to increase the efficiency of assisted reproductive technologies. This study evaluated the pharmacokinetics, pharmacodynamics, and cardiac safety of nolasiban in 45 healthy wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e1e0c6bc1df476b79c7c40414930d3c
https://doaj.org/article/941c758ff82c46db9ab0bd9fda565dc9
https://doaj.org/article/941c758ff82c46db9ab0bd9fda565dc9
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0163020 (2016)
INTRODUCTION:Rupatadine is a marketed second generation antihistamine, with anti-PAF activity, indicated for symptomatic treatment of allergic rhinitis and urticaria. This study was conducted to evaluate the pharmacokinetics (PK), pharmacodynamics (P
Externí odkaz:
https://doaj.org/article/449169c79d604245831c95e8c59145d5